Engflag

Efavirenz

Quick links to important sections

Efavirenz

Selected form

Efavirenz_EN

Method of action: Antivirals For Systemic Use

Treatment option: Immunodeficiency, Infection

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Efavirenz

Quick Facts

Property Description
Active ingredient Efavirenz (EFV)
Form Oral Tablet, Capsule, Suspension
Pharmacological class Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Common use Management of HIV Infection
Origin Synthetic Compound

Efavirenz, or EFV, is a crucial prescription-only medication categorized as an antiretroviral agent. Its fundamental purpose is to manage and control the progression of the Human Immunodeficiency Virus (HIV) infection. The drug was first approved in 1998, establishing its long-standing efficacy in suppressing the virus. This status confirms its clinically recognized role as a foundational medication in combination regimens.

Efavirenz: Classification and Core Identity

Efavirenz belongs to the specific pharmacological class known as a non-nucleoside reverse transcriptase inhibitor (NNRTI). This classification identifies the drug as a synthetic compound designed to fight the virus by targeting a specific enzyme. As a single-ingredient product, Efavirenz provides the necessary active component for combination therapy. Efavirenz is recognized internationally as an essential medicine.

The drug’s unique identity as an NNRTI stems from its ability to disrupt the viral lifecycle in a distinct way compared to other classes of HIV medication, such as nucleoside reverse transcriptase inhibitors, supporting its use in preventing the progression of the infection.

What is the General Purpose of Efavirenz?

The general purpose of Efavirenz is to limit the spread of HIV within the body by directly blocking a key step in the viral lifecycle. Efavirenz works by acting as a specific inhibitor that jams the reverse transcriptase enzyme, which the virus needs to copy its genetic material. This action effectively blocks viral replication at an early stage, which is the cornerstone of successful HIV management.

This action helps decrease the amount of HIV in the blood, allowing the immune system to recover. This benefit allows the immune system to stabilize and better combat opportunistic infections, which represents the typical use scenario in managing the underlying condition.

Regulatory References

  1. Efavirenz on the WHO Essential Medicines List

What side effects are possible with Efavirenz?

Efavirenz: Documented Safety Profile

The official safety profile of Efavirenz is structured by government regulatory agencies (such as the FDA and EMA) based on documented adverse reactions and their frequency. The profile emphasizes the classification of adverse events by System-Organ-Class, focusing heavily on central nervous system, psychiatric, and dermatological effects.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on incidence rates documented in clinical trials and post-marketing surveillance. Very Common (ge 1/10) effects include rash, dizziness, headache, fatigue, and nausea. Effects classified as Common (ge 1/100 to <1/10) include anxiety, depression, insomnia, vivid dreams, vomiting, diarrhea, and elevated blood lipids such as hypertriglyceridemia.

Clinically Significant and Serious Events

Official regulatory documents identify certain rare but serious adverse reactions. These include severe dermatologic reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Serious psychiatric adverse events, including psychosis and suicidal ideation, are also documented in the safety profile. Significant hepatotoxicity and convulsions represent other serious events noted in regulatory texts.

Time-Related Patterns and Restrictions

Specific time-related safety patterns are noted: Nervous system and psychiatric symptoms are often most frequent and intense during the first 2 to 4 weeks of treatment and typically decrease with continued use. The regulatory label includes explicit restrictions and contraindications, notably prohibiting use in individuals with known severe hypersensitivity to Efavirenz and in those with pre-existing severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes Efavirenz overdosage as resulting primarily in an exaggeration of known dose-related adverse effects, specifically those involving the nervous system. Documented manifestations can include intensifying symptoms such as dizziness, insomnia, somnolence, impaired concentration, and abnormal dreaming.

Official Emergency Response

Management of overdosage requires immediate medical attention. Regulators advise contacting a local poison control center right away or seeking the nearest hospital emergency room for any suspected overdose.

Urgent medical help is required immediately if an individual exhibits severe or life-threatening symptoms, including collapse, having a seizure (convulsions), experiencing trouble breathing, or becoming unconscious (cannot be awakened).

Overdose Management

Element Regulatory Statement
Antidote Status No specific antidote is known or available for efavirenz overdose.
Supportive Measures Management consists of general supportive measures.
Procedural Note The removal of unabsorbed drug (e.g., via activated charcoal) may be appropriate due to the drug's long terminal half-life.

Patients with mild hepatic impairment should be monitored carefully for dose-related nervous system symptoms following potential overexposure.

Therapeutic Uses of Efavirenz

Quick Facts: Therapeutic Domains

  • Human Immunodeficiency Virus (HIV-1): Used to help manage and treat HIV-1 infection in adults and in children of eligible age and weight.
  • Combination Therapy: Used exclusively alongside other suitable antiretroviral agents to help achieve optimal therapeutic outcomes.

What Efavirenz treats: main uses and benefits

Efavirenz is a core medication used in combination with other antiretroviral agents to help manage Human Immunodeficiency Virus type 1 (HIV-1) infection. The primary goal of this therapeutic approach is to help reduce the presence of HIV in the bloodstream. This reduction helps support the body's immune system, potentially resulting in a stronger ability to fight infection.

The medication is indicated for the treatment of HIV-1 infection in adults and in pediatric patients who meet specific age and weight criteria. It is a fundamental component of established antiretroviral therapy (ART) regimens. Adherence to a combination regimen that includes efavirenz may help to extend the duration of healthier living and may help lower the risk of developing conditions associated with advanced HIV infection. Efavirenz is not a cure for HIV, but its proper use helps to maintain viral suppression, which is essential for managing the long-term progression of the condition.

The use of efavirenz requires ongoing consultation with a healthcare professional to determine suitability and to monitor progress.

Eligibility and Restrictions for Use

The eligibility for Efavirenz is strictly defined by regulatory guidelines, focusing on absolute exclusions and specific patient criteria.

Contraindications and Exclusions

Classification Who Must Not Use Efavirenz
Absolute Contraindications Individuals with known hypersensitivity to Efavirenz or its components. Patients with severe hepatic impairment (Child-Pugh Class C). Co-administration with certain drugs (e.g., voriconazole, ergot derivatives, cisapride) is prohibited.
Prohibited Use As monotherapy (must be combined with other antiretroviral agents).
Not Recommended Status Patients with moderate hepatic impairment (Child-Pugh Class B). Women in the first trimester of pregnancy. Women who are breastfeeding.

Eligibility Criteria and Limitations

Population Group Eligibility Status
Pediatric Patients Approved for those 3 months of age and older and weighing at least 3.5 kg. Safety and efficacy are not established below these limits.
Adults and Adolescents Established use. Caution advised in those with a history of seizures or significant psychiatric disorders.
Pregnancy Women of childbearing potential should use effective contraception due to the potential for fetal harm during the first trimester.

These guidelines establish clear boundaries: the medicine is prohibited for severe liver disease and specific co-medications, and its use is restricted based on minimum age/weight and reproductive status to maintain patient safety as defined by official health authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Efavirenz interactions are primarily defined by its effect on liver enzyme systems, leading to a number of critical restrictions and requirements for co-administered substances.

Regulatory Interaction Classifications

Category Key Constraints
Contraindicated Combinations Co-administration is forbidden for drugs highly dependent on CYP3A4 for clearance, where loss of effect or serious adverse events (e.g., cardiac arrhythmias, prolonged sedation) could occur. This includes ergot derivatives, cisapride, midazolam, and certain Hepatitis C antivirals (e.g., elbasvir/grazoprevir).
Exposure Modification Efavirenz is a potent inducer of CYP3A4 and CYP2B6. This activity significantly decreases the plasma concentration and therapeutic effect of many co-administered drugs that are substrates of these enzymes. Dose adjustments are frequently required for drugs such as voriconazole and methadone.
Pharmacodynamic Effects Caution is advised with drugs that prolong the QTc interval or cause Central Nervous System (CNS) effects, due to potential additive risks.
Food and Herbal Products Efavirenz should be taken on an empty stomach to minimize increased plasma concentrations, which may raise the risk of adverse reactions. St. John's wort is contraindicated due to its strong potential to reduce Efavirenz levels.

Essential Interaction Context

The interaction profile requires careful review for all new prescriptions to prevent loss of efficacy or serious adverse reactions. The strong enzyme induction status of Efavirenz necessitates either dose increases for the co-administered drug or selection of alternative medications not metabolized by CYP3A4 or CYP2B6.

Mechanism of Action

Targeted Inhibition of the Reverse Transcriptase Enzyme

Efavirenz functions as a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI). Its primary action is to bind non-covalently to a specific allosteric site within the hydrophobic pocket of the HIV-1 Reverse Transcriptase (RT) enzyme. This binding induces a critical conformational change in the enzyme's structure, which physically prevents the RT enzyme from performing its function of DNA polymerization. This action directly inhibits the enzyme's ability to convert the viral RNA genome into proviral DNA.

Disruption of the Viral Genetic Replication Pathway

The molecular inhibition of RT halts a critical early step in the viral replication cycle. By preventing the synthesis of proviral DNA, Efavirenz eliminates the material required for the virus to integrate its genetic code into the host cell's chromosomes. This disruption of the viral genetic pathway reduces the formation and release of new viral particles from infected host cells. Consequently, this leads to decreased concentrations of replicating virus within systemic circulation.

Mechanism Specificity and Viral Resistance

This mechanism is highly specific to the enzyme structure found in HIV-1 and does not inhibit the Reverse Transcriptase of HIV-2. Furthermore, the binding site is susceptible to rapid alteration by viral mutations. Changes to key amino acids in the binding pocket diminish Efavirenz's affinity, thereby compromising the inhibitory mechanism and allowing the replication pathway to resume.

Dosage and Administration Information

Efavirenz is an oral medication that must be used strictly as part of a combination antiretroviral regimen; it is never administered as a single agent.

Standard Dosing and Administration Rules

Patient Group Recommended Daily Dose Administration Condition
Adults (≥ 40 kg) 600 mg once daily Must be taken on an empty stomach, preferably at bedtime.
Pediatric (≥ 3.5 kg) Dose is weight-based, ranging from 100 mg to 400 mg once daily. Must be taken on an empty stomach; use of capsule contents with food is possible for those unable to swallow.

The standard adult dose is 600 mg, taken once daily. The use of efavirenz is recommended on an empty stomach to manage drug concentrations, and administration at bedtime is advised.

Tablets must be swallowed whole and must not be crushed or broken. For pediatric patients or adults unable to swallow the solid dosage forms, the contents of the efavirenz capsules may be mixed with a small amount (1–2 teaspoons) of soft food or infant formula. After taking this mixture, no additional food should be consumed for 2 hours.

Dosage Adjustments and Duration

Efavirenz is approved for use in pediatric patients starting at 3 months of age and weighing at least 3.5 kg. Dosing for children weighing less than 40 kg is determined by body weight, ensuring appropriate dosage.

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; doses should not be doubled. The therapy is intended for continuous, long-term use as part of the overall antiretroviral treatment protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Efavirenz

This overview summarizes the research that has been conducted to study Efavirenz as part of a combination regimen for managing HIV-1 infection. The research is focused on what was studied, the patterns observed in these studies, and what aspects of the research base remain less certain according to official data.

Evidence for Use in HIV-1 Infection

Research for Efavirenz primarily consists of numerous Randomized Controlled Trials (RCTs). These studies examine Efavirenz-based combinations compared to other standard treatments. The findings from these trials have also been synthesized in Systematic Reviews and Meta-analyses, which combine data from multiple studies, as research examined Efavirenz-based combinations compared to other standard treatments.

In these studies, researchers focused on virologic outcomes, tracking the amount of Human Immunodeficiency Virus (HIV) in the blood (viral load). They also monitored immunologic outcomes, tracking changes in CD4+ T-cell counts. Studies monitored patterns related to viral load and research described how CD4+ T-cell counts evolved in the observed populations during the study period. The research also monitored severe clinical outcomes, such as outcomes related to the progression of the condition or death. Evidence derived from these studies contributes to the broader evidence landscape for Efavirenz when studied as part of combination antiretroviral therapy for individuals starting treatment for the first time (treatment-naive adults).

Comparison of Efavirenz Regimens in Clinical Trials

Studies explored how Efavirenz-based regimens performed when compared directly to other established antiretroviral drug combinations. These comparative trials focused on exploring whether the different regimens were associated with similar virologic results. One key aspect of these trials is that they often reported a higher rate of participant discontinuation in the Efavirenz group than in those taking specific comparator drug classes. This means that a greater number of people stopped taking the Efavirenz-based regimen, which means the comparative evidence is lacking for those individuals and can affect the final study conclusions.

Evidence in Special Populations and Uncertainties

Efavirenz was evaluated in dedicated studies involving children and adolescents who were starting antiretroviral therapy for the first time. However, research is limited, and research is not established in infants younger than 3 months of age or those weighing less than 3.5 kg. Furthermore, research focusing on certain populations monitored major interindividual variability in plasma drug concentrations in children.

Data for certain groups remain insufficient, and there is also limited information for long-term outcomes in the older adult population because this group was not the primary focus of the initial pivotal trials. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Efavirenz (FAQ)

Q: What is Efavirenz used for?

A: Efavirenz is a type of medicine classified as a non-nucleoside reverse transcriptase inhibitor (NNRTI). It is used in combination with other antiretroviral agents as part of a treatment regimen for human immunodeficiency virus (HIV-1) infection in adults and children who meet the criteria for treatment.

Q: How does Efavirenz work?

A: Efavirenz works by interfering with an enzyme called reverse transcriptase, which is essential for the HIV virus to make copies of itself. By inhibiting this enzyme, the drug helps to reduce the amount of HIV in the blood. This mechanism is intended to support the body's immune system.

Q: What are some potential side effects of Efavirenz?

A: As with many medications, Efavirenz is associated with potential side effects. Commonly reported effects have included rash, dizziness, difficulty sleeping, and fatigue. More significant but less common effects may involve changes in mental health or liver enzyme levels. Individuals experiencing concerning symptoms should consult a healthcare professional.

Q: Can Efavirenz interact with other medicines?

A: Efavirenz has the potential to interact with a wide variety of prescription and non-prescription medicines, including herbal products. These interactions can affect how Efavirenz or the other medicine works. It is important to disclose all current medications to a qualified healthcare provider before starting or stopping any regimen involving Efavirenz.

How should Efavirenz be stored and disposed of?

Official Storage and Disposal Requirements for Efavirenz

This information reflects the mandatory storage and disposal instructions based on regulatory labeling from authoritative government sources.

Storage Component Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), avoiding excessive heat.
Protection Keep the medicine in its original container and keep the container tightly closed to protect it from moisture.
Child Safety Keep Efavirenz out of the reach of children.
Disposal Do not flush or dispose of in household trash. Discard unused or expired product according to national/local disposal guidelines (e.g., drug take-back programs).

Storage within the specified temperature range and maintaining the container's integrity are essential for preserving product stability until the expiry date. Official guidelines mandate that unused or expired Efavirenz must be disposed of through controlled programs to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

flagUSA

Equivalent of Efavirenz found in:

A-Z Index: